Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients

Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma

Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma

The need for improved healthcare infrastructure for extranodal NK/T-cell lymphoma in Latin America

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results

High-fibre dietary intervention in precursor plasma cell disorders improves biomarkers of disease, may delay progression to myeloma

Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD

KRdc as induction therapy shows improved OS for NDMM patients

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL

Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma

Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM

Pembrolizumab after chemo demonstrates promising activity in low-risk cHL

Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtagene vicleucel therapy for RRMM

Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in RRMM

Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy

Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM

Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma

Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL

Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML master trial in the venetoclax/azacitidine age

IDH2 mutation associated with favourable outcome in older adults with newly diagnosed ALL treated with lower-intensity therapy

Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements

Beat AML master trial update: A clinical trial for acute myeloid leukaemia

Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone